Your session is about to expire
← Back to Search
Zanubrutinib for Immunoglobulin-Related Disease
Study Summary
This trial will test whether zanubrutinib is safe and effective in treating patients with a disease related to IgG4.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken drugs like infliximab, abatacept, or tocilizumab in the last 56 days.I haven't taken BTK inhibitors in the last 6 months.I have not taken JAK inhibitor medication in the last 28 days.My IgG4-related disease in the salivary or tear glands is confirmed by a biopsy.I have an autoimmune disease that could affect study results, except for IgG4-related disease.I have had cancer before, but it was not skin, cervical, prostate, or colon cancer, or it was cured more than 5 years ago.I have not used B cell depleting therapy like rituximab in the last year.I am not on immunosuppressive drugs, except for prednisone or its equivalent, at a stable dose for the last 28 days.I do not have active tuberculosis, HIV, or hepatitis B/C.I haven't taken any strong immune or cancer drugs in the last 28 days.I am between 18 and 85 years old.I haven't taken any synthetic DMARDs like methotrexate in the last 28 days.My glucocorticoid dose has been stable for the last 28 days.
- Group 1: Zanubrutinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is participation in this study currently being sought?
"Affirmative. According to clinicaltrials.gov, the trial is actively searching for subjects since its inception on August 1st 2022 and last update on October 24th 2022. The research requires 10 patients from a single medical centre."
What is the scope of this research project in terms of participants?
"Affirmative. The information accessible on clinicaltrials.gov indicates that this medical inquiry, which was initially uploaded to the website on August 1st 2022, is actively seeking out participants. A total of 10 patients are required from a single site for successful enrollment."
Has the FDA sanctioned Zanubrutinib 80 MG for general consumption?
"Our assessment of Zanubrutinib 80 MG's safety factor has been set to 2, as this Phase 2 trial only provides limited evidence of its security. There is currently no data proving the effectiveness of this medication."
Has this kind of clinical trial ever been conducted before?
"Since its initial research in 2016, Zanubrutinib 80 MG has been approved by Phase 1 and is now under consideration for further clinical trials. MEI Pharma, Inc., initially sponsored the study with 177 participants; since then, 37 live studies have taken place across 324 cities and 32 countries worldwide."
What criteria must a person fulfill in order to be eligible for this clinical research?
"To qualify for this clinical trial, individuals should have been diagnosed with immunoglobulin g4-related disease and must be between 18 to 85 years of age. The team is looking to recruit approximately 10 participants."
What other investigations have taken place concerning Zanubrutinib 80 MG?
"Presently, 8 Phase 3 trials are researching the effects of Zanubrutinib 80 MG. While Palo Alto, California is one location with an active study for this drug, a total of 1104 sites have been deployed for research purposes."
What medical applications does Zanubrutinib 80 MG typically have?
"The medication zanubrutinib 80 MG is often prescribed to those suffering from Waldenstrom macroglobulinemia. Additionally, it has been found to be effective in treating lymphoma and relapsed marginal zone lymphoma after one prior therapy session."
Are people aged 30 and above eligible for this research endeavor?
"This clinical trial has an age range of 18-85 years old, with no exceptions."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger